The Utility of PD-L1/CD8 Dual Immunohistochemistry for Prediction of Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Rosenbaum, Matthew
Khosrowjerdi, Sara [1 ]
Kem, Marina [2 ]
Kamesan, Vashine [2 ]
Digumarthy, Subba [2 ]
Gainor, Justin [2 ]
Mino-Kenudson, Mari [2 ]
机构：
[1] Tufts Sch Med, Boston, MA USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
LABORATORY INVESTIGATION | 2019年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1868
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The Utility of PD-L1/CD8 Dual Immunohistochemistry for Prediction of Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)
    Rosenbaum, M.
    Khosrowjerdi, S.
    Kamesan, V.
    Digumarthy, S.
    Gainor, J.
    Mino-Kenudson, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S533 - S533
  • [2] The Utility of PD-L1/CD8 Dual Immunohistochemistry for Prediction of Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)
    Rosenbaum, Matthew
    Khosrowjerdi, Sara
    Kem, Marina
    Kamesan, Vashine
    Digumarthy, Subba
    Gainor, Justin
    Mino-Kenudson, Mari
    MODERN PATHOLOGY, 2019, 32
  • [3] Utility of Programmed Cell Death Ligand 1 (PD-L1)/CD8 Dual Immunohistochemistry (IHC) in Predicting Response to Immunotherapy in Lung Cancer
    Rosenbaum, Matthew
    Huynh, Tiffany
    Kem, Marina
    Gainor, Justin
    Mino-Kenudson, Mari
    MODERN PATHOLOGY, 2018, 31 : 748 - 748
  • [4] Utility of Programmed Cell Death Ligand 1 (PD-L1)/CD8 Dual Immunohistochemistry (IHC) in Predicting Response to Immunotherapy in Lung Cancer
    Rosenbaum, Matthew
    Huynh, Tiffany
    Kem, Marina
    Gainor, Justin
    Mino-Kenudson, Mari
    LABORATORY INVESTIGATION, 2018, 98 : 748 - 748
  • [5] PD-L1 Immunohistochemistry as Biomarker in Non-Small Cell Lung Cancer (NSCLC)
    Krenbek, Dagmar
    Weidinger, Barbara
    Jarius, Christa
    Holzer, Sophia
    Fabican, Hannah
    Mohn-Staudner, Andrea
    Hochmair, Maximilian
    Chott, Andreas
    Setinekl, Ulrike
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S430 - S430
  • [6] Screening for PD-L1 expression by immunohistochemistry in non-small cell lung cancer (NSCLC) in the era of immunotherapy: a national study
    Breen, K.
    McCormack, J.
    Fabre, A.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2017, 186 : S417 - S418
  • [7] Screening for PD-L1 expression by immunohistochemistry in non-small cell lung cancer (NSCLC) in the era of immunotherapy: a national study
    Breen, K.
    McCormack, J.
    Fabre, A.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2017, 186 (SUPPL 10) : S417 - S418
  • [8] Current PD-L1 immunohistochemistry for non-small cell lung cancer
    Scheel, Andreas H.
    Schaefer, Stephan C.
    JOURNAL OF THORACIC DISEASE, 2018, 10 (03) : 1217 - 1219
  • [9] PD-L1 immunohistochemistry in patients with non-small cell lung cancer
    Jotatsu, Takanobu
    Oda, Keishi
    Yatera, Kazuhiro
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S2127 - S2129
  • [10] Efficacy of anti-PD1/PD-L1 immunotherapy in non-small cell lung cancer is dependent upon Immunoscore IC CD8 and PD-L1 status
    Galon, Jerome
    Bibeau, Frederic
    Greillier, Laurent
    Fumet, Jean David
    Ilie, Alis
    Monville, Florence
    Lauge, Caroline
    Catteau, Aurelie
    Boquet, Isabelle
    Majdi, Amine
    Oulkhouir, Youssef
    Brandone, Nicolas
    Adam, Julien
    Sbarrato, Thomas
    Kassambara, Alboukadel
    Fieschi, Jacques
    Garcia, Stephane
    Lepage, Anne Laure
    Tomasini, Pascale
    Ghiringhelli, Franc Commacis
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345